Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigeki Yagyu

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Pediatric Surgery International|December 9, 2022
Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse modelKosuke Kambe, Masafumi Iguchi, Mayumi Higashi, et al.
Oncology Reports|November 15, 2016
MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cellsOsamu Otabe, Ken Kikuchi, Kunihiko Tsuchiya, et al.
British Journal of Cancer|March 23, 2026
Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1Yuya Sugitatsu, Akimasa Tomida, Masaya Suematsu, et al.
Scientific Reports|September 23, 2021
Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcomaTakuyo Kanayama, Mitsuru Miyachi, Yohei Sugimoto, et al.
Biochemical and Biophysical Research Communications|August 11, 2010
Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcomaMitsuru Miyachi, Kunihiko Tsuchiya, Hideki Yoshida, et al.
Cancer Science|August 12, 2021
Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastomaAkimasa Tomida, Shigeki Yagyu, Kayoko Nakamura, et al.
Biochemical and Biophysical Research Communications|March 25, 2019
Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcomaNorio Nakagawa, Ken Kikuchi, Shigeki Yagyu, et al.
Molecular Therapy Oncolytics|April 28, 2016
Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapyLisa Farzad, Vincenzo Cerullo, Shigeki Yagyu, et al.
Journal of Medical Case Reports|September 3, 2019
Effective heart-sparing whole lung irradiation using volumetric modulated arc therapy: a case reportGen Suzuki, Toshiyuki Ogata, Norihiro Aibe, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 15, 2015
[Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation]Mayumi Hatsuse, Kyoko Taniguchi-Yoshihara, Shigeki Yagyu, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Pediatric Surgery International|December 9, 2022
Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse modelKosuke Kambe, Masafumi Iguchi, Mayumi Higashi, et al.
Oncology Reports|November 15, 2016
MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cellsOsamu Otabe, Ken Kikuchi, Kunihiko Tsuchiya, et al.
British Journal of Cancer|March 23, 2026
Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1Yuya Sugitatsu, Akimasa Tomida, Masaya Suematsu, et al.
Scientific Reports|September 23, 2021
Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcomaTakuyo Kanayama, Mitsuru Miyachi, Yohei Sugimoto, et al.
Biochemical and Biophysical Research Communications|August 11, 2010
Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcomaMitsuru Miyachi, Kunihiko Tsuchiya, Hideki Yoshida, et al.
Cancer Science|August 12, 2021
Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastomaAkimasa Tomida, Shigeki Yagyu, Kayoko Nakamura, et al.
Biochemical and Biophysical Research Communications|March 25, 2019
Mutations in the RAS pathway as potential precision medicine targets in treatment of rhabdomyosarcomaNorio Nakagawa, Ken Kikuchi, Shigeki Yagyu, et al.
Molecular Therapy Oncolytics|April 28, 2016
Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapyLisa Farzad, Vincenzo Cerullo, Shigeki Yagyu, et al.
Journal of Medical Case Reports|September 3, 2019
Effective heart-sparing whole lung irradiation using volumetric modulated arc therapy: a case reportGen Suzuki, Toshiyuki Ogata, Norihiro Aibe, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 15, 2015
[Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation]Mayumi Hatsuse, Kyoko Taniguchi-Yoshihara, Shigeki Yagyu, et al.
Pageof 7